Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population
CONCLUSIONS: These findings support the conclusion that DOACs are an appropriate and effective drug class for the management of VTE in patients with obesity.PMID:37994550 | DOI:10.1177/10600280231212186 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 23, 2023 Category: Drugs & Pharmacology Authors: Courtney S Pilkerton Megan Adelman Emily Crocetti Jun Xiang Victoria Strick Charles D Ponte Shaylee Peckens Benjamin P Jackson Kylen Whipp Amie M Ashcraft Source Type: research
A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience
CONCLUSIONS: Optimizing use of current therapies, as well as identifying and advancing novel therapeutic modalities such as eculizumab, are vital for the improvement of AMR prevention and treatment in LTRs to extend long-term allograft function and survival.PMID:37994573 | DOI:10.1177/10600280231213112 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 23, 2023 Category: Drugs & Pharmacology Authors: Hanna L Kleiboeker Alyson Prom Krista Paplaczyk Catherine N Myers Source Type: research
Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B
CONCLUSION: Valoctocogene and etranacogene provide another treatment for selected patients with hemophilia. Treatment for the patient with hemophilia (gene therapy vs replacement strategy) must be personalized as new clinical data are published being cognizant of drug affordability.PMID:37978816 | DOI:10.1177/10600280231202247 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 18, 2023 Category: Drugs & Pharmacology Authors: John A Dougherty Kristiann M Dougherty Source Type: research
Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B
CONCLUSION: Valoctocogene and etranacogene provide another treatment for selected patients with hemophilia. Treatment for the patient with hemophilia (gene therapy vs replacement strategy) must be personalized as new clinical data are published being cognizant of drug affordability.PMID:37978816 | DOI:10.1177/10600280231202247 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 18, 2023 Category: Drugs & Pharmacology Authors: John A Dougherty Kristiann M Dougherty Source Type: research
Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B
CONCLUSION: Valoctocogene and etranacogene provide another treatment for selected patients with hemophilia. Treatment for the patient with hemophilia (gene therapy vs replacement strategy) must be personalized as new clinical data are published being cognizant of drug affordability.PMID:37978816 | DOI:10.1177/10600280231202247 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 18, 2023 Category: Drugs & Pharmacology Authors: John A Dougherty Kristiann M Dougherty Source Type: research
Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B
CONCLUSION: Valoctocogene and etranacogene provide another treatment for selected patients with hemophilia. Treatment for the patient with hemophilia (gene therapy vs replacement strategy) must be personalized as new clinical data are published being cognizant of drug affordability.PMID:37978816 | DOI:10.1177/10600280231202247 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 18, 2023 Category: Drugs & Pharmacology Authors: John A Dougherty Kristiann M Dougherty Source Type: research
Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation
CONCLUSION AND RELEVANCE: The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.PMID:37960871 | DOI:10.1177/10600280231211306 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 14, 2023 Category: Drugs & Pharmacology Authors: Zi Wang Xiaoyu Li Ye Zou Xiaoye Li Qianzhou Lv Source Type: research
Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation
CONCLUSION AND RELEVANCE: The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.PMID:37960871 | DOI:10.1177/10600280231211306 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 14, 2023 Category: Drugs & Pharmacology Authors: Zi Wang Xiaoyu Li Ye Zou Xiaoye Li Qianzhou Lv Source Type: research
Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation
CONCLUSION AND RELEVANCE: The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.PMID:37960871 | DOI:10.1177/10600280231211306 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 14, 2023 Category: Drugs & Pharmacology Authors: Zi Wang Xiaoyu Li Ye Zou Xiaoye Li Qianzhou Lv Source Type: research
Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation
CONCLUSION AND RELEVANCE: The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.PMID:37960871 | DOI:10.1177/10600280231211306 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 14, 2023 Category: Drugs & Pharmacology Authors: Zi Wang Xiaoyu Li Ye Zou Xiaoye Li Qianzhou Lv Source Type: research
Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia
CONCLUSIONS AND RELEVANCE: This study represents the first head-to-head comparison of patiromer and SZC in the setting of acute hyperkalemia. No difference in effectiveness between patiromer and SZC in reducing serum potassium was seen. Both agents can be considered in acute hyperkalemia management.PMID:37953506 | DOI:10.1177/10600280231209968 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Alison Rydell Corianne Thackrey Maryam Molki Brandon P Mullins Source Type: research
Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia
CONCLUSIONS AND RELEVANCE: This study represents the first head-to-head comparison of patiromer and SZC in the setting of acute hyperkalemia. No difference in effectiveness between patiromer and SZC in reducing serum potassium was seen. Both agents can be considered in acute hyperkalemia management.PMID:37953506 | DOI:10.1177/10600280231209968 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Alison Rydell Corianne Thackrey Maryam Molki Brandon P Mullins Source Type: research
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research
